Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).

Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H.

Exp Hematol Oncol. 2012 Nov 9;1(1):33. doi: 10.1186/2162-3619-1-33.

2.

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.

Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ.

Leukemia. 1998 Dec;12(12):2006-14.

PMID:
9844931
3.

Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR).

Weber A, Taube S, Starke S, Bergmann E, Christiansen NM, Christiansen H.

J Clin Invest. 2011 Feb;121(2):545-53. doi: 10.1172/JCI44415.

4.
5.
6.

tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.

Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaansen HJ, van Wering ER, van Dongen JJ.

Leukemia. 1993 Dec;7(12):2004-11.

PMID:
8255100
7.

The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.

de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER, van Dongen JJ, van den Berg H, van der Schoot CE.

Br J Haematol. 2002 Jan;116(1):87-93.

PMID:
11841400
8.

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia.

Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, van Wering ER, van Dongen JJ, van der Schoot CE.

Leukemia. 2000 Aug;14(8):1426-35.

PMID:
10942239
9.

Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.

van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H.

Leukemia. 1992;6 Suppl 1:47-59. Review.

PMID:
1548936
11.

Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia.

Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G.

Leukemia. 2000 Feb;14(2):316-23.

PMID:
10673751
12.

Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.

Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG.

Blood. 1997 Nov 15;90(10):4212-21.

13.

[A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].

Wang L, Zhang LP, Li ZG, Cheng YF, Tian KG, Lu AD.

Zhonghua Er Ke Za Zhi. 2005 Mar;43(3):170-3. Chinese.

PMID:
15833185
14.

Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.

Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG.

Blood. 2000 Apr 15;95(8):2651-8.

15.

MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.

van der Velden VH, van Dongen JJ.

Methods Mol Biol. 2009;538:115-50. doi: 10.1007/978-1-59745-418-6_7.

PMID:
19277574
16.

Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE.

Leukemia. 1995 Oct;9(10):1726-34.

PMID:
7564517
17.
18.

[Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].

Jia YP, Liu GL, Zhang LP.

Zhonghua Er Ke Za Zhi. 2004 Aug;42(8):600-4. Chinese.

PMID:
15347448
19.

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.

van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ.

Leukemia. 2002 Aug;16(8):1432-6.

20.

[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].

zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.

Klin Padiatr. 2000 Jul-Aug;212(4):169-73. German.

PMID:
10994545
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk